Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics Inc (NQ: RLAY )

8.220 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 8.220
Bid (Size) 8.220 (4)
Ask (Size) 9.250 (1)
Prev. Close 8.220
Today's Range 8.220 - 8.220
52wk Range 5.700 - 12.46
Shares Outstanding 121,613,181
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets

Performance

YTD
-30.66%
-30.66%
1 Month
+28.44%
+28.44%
3 Month
+23.42%
+23.42%
6 Month
-11.14%
-11.14%
1 Year
-30.98%
-30.98%

More News

Read More
These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
Via Talk Markets
Expert Ratings For Relay Therapeutics
Via Benzinga
Expert Ratings For Relay Therapeutics
Via Benzinga
Key Takeaways From Relay Therapeutics Analyst Ratings
Via Benzinga
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Via Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
Via Talk Markets
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
From Relay Therapeutics, Inc.
Via GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
Via Talk Markets
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
5 Of 7 AI Categories Rose, Slightly,Over Past Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 7 AI Categories Declined, On Average, The First Week Of May
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Via Talk Markets
RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Via Talk Markets
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.